Corrigendum to “The member of the cyclic di-nucleotide family bis-(3′,5′)-cyclic dimeric inosine monophosphate exerts potent activity as mucosal adjuvant” [Vaccine 28 (2010) 2249–2258]

Adjuvant physiochemistry and advanced nanotechnology for vaccine development

“…312 Guzman and colleagues extensively explored the immunological profiles of CDN-based adjuvants and vaccines. [313][314][315][316][317] In 2007, the c-di-GMP adjuvant, for the first time, demonstrated its capability in producing both cellular and humoral immune responses against antigens. 313 Intranasal administration of c-di-GMP and OVA induced antigen-specific CTLs and CD4 + T cells as well as mucosal IgA responses in lungs and vaginas.…”

Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies

“…They are reported to interact with the transmembrane protein stimulator of interferon genes (STING), which then increases the production of type I interferons and further drives the adaptive immune response (Ishikawa et al, 2009 ; Burdette et al, 2011 ; Shaw et al, 2013 ). Studies of intranasal delivery of model protein antigens such as recombinant influenza nucleoprotein (rNP), β-Gal and OVA together with the adjuvant c-di-AMP/IMP in mice suggest them as potent mucosal adjuvants, especially when cellular immunity is desired (Ebensen et al, 2007 ; Libanova et al, 2010 ; Ebensen et al, 2011 ; Sanchez et al, 2014 ). C-di-GMP can enhance the immune response in mice for H5N1 virosomes after sublingual, intranasal and intramuscular administrations (Pedersen et al, 2011 ).…”

(3′-5′)-Cyclic Dinucleotides: Synthetic Strategies and Biological Potential

“…127 c-di-IMP (4) has been prepared enzymatically from c-di-AMP (2) by use of adenosine-deaminase. 25,26…”

“…However, in vitro studies have evidenced that retroviral integrases can generate cyclic deoxydinucleotides during the 3′-end processing of viral DNA. − Such release seriously supports the possibility of their natural occurrence and has triggered the search of cyclic dinucleotides as new drugs acting by inhibition of viral integrases. Additionally, c-di-IMP ( 4 ), the synthetic inosine-containing analogue of c-di-GMP, displays adjuvant properties promising for development of mucosal vaccination strategies. , …”

“…Additionally, c-di-IMP (4), the synthetic inosine-containing analogue of c-di-GMP, displays adjuvant properties promising for development of mucosal vaccination strategies. 25,26 The biology of c-di-GMP constitutes a new and rapidly evolutive field that has fueled inspiration of chemists for innovative synthetic approaches regarding (3′-5′)-cyclic dinucleotides (c-di-GMP, c-di-AMP, or synthetic (3′-5′)-cyclic dinucleotides incorporating natural nucleobases) and analogues.…”